This article was originally published in The Gray Sheet
Company reps meet with FDA June 4 to discuss a trial design for the Artic Circler atrial fibrillation ablation catheter; firm hopes to begin an IDE trial later this year. The meeting came two days after FDA's Circulatory System Devices Panel unanimously voted against recommending approval of Cardima's Revelation Tx AF ablation catheter, largely due to difficulties in obtaining AF burden data from patients (1"The Gray Sheet" June 2, 2003, p. 3)...
You may also be interested in...
The ability of self-reporting to accurately track reduction in atrial fibrillation burden is cast into doubt by FDA panel experience with Cardima's Revelation ablation system data submission
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.